Merck entered into an exclusive licensing deal with Hanmi Pharmaceutical for the development, manufacture and commercialization of efinopegdutide for nonalcoholic steatohepatitis (NASH).

Two years after AbbVie and Voyager Therapeutics first forged a collaboration to develop treatments for Alzheimer’s disease, the partnership came to an end after AbbVie terminated the agreement.

According to a study published in the journal Science Advances, an international team of researchers led by neuroscientists at Harvard Medical School uncovered which olfactory cell types are most vulnerable to infection by SARS-CoV-2, which causes Covid-19.

Gene therapy pioneer uniQure launched the first-in-human adeno-associated virus-based gene therapy clinical trial for Huntington’s disease.

Novartis CAR-T cell therapy Kymriah met the primary endpoint at an interim analysis of a phase II trial in patients with relapsed or refractory follicular lymphoma, the Swiss drugmaker said.

Russia’s minister of health, Mikhail Murashko, indicated that the country is planning a nationwide program to vaccinate its population against Covid-19 starting in October.